Divalproex Sodium
Product Images NDC 70518-3459

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-3459). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Mm2 (Divalproex Sodium 250mg 70518 3459 01)

Mm2 (Divalproex Sodium 250mg 70518 3459 01)
This is a description of Divalproex Sodium delayed-release tablet, with a strength of 250 mg, supplied in a pack of 1. The tablets should be swallowed whole and not crushed or chewed. The medication is categorized as a Valproic Acid Activity Orepack HD2, and is available only with a prescription. The NDC number for this drug is 70518-3459-01, and the lot number and expiry date are not available in the given text. The manufacturer is Upsher-Smith Labs, Inc. of Minneapolis, MN, and the drug should be kept out of the reach of children. The package insert should be consulted for further instructions, and the drug should be stored at 20-25°C (88-77°F), with excursions permitted to 15-30°C (59-86°F) [according to USP]. The drug has been repackaged by RemedyRepack Inc. of Indiana, PA, and their contact number is 724.465.8762.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Divalproex Sodium is a delayed-release tablet used for Valproic Acid activity. Each box contains 100 tablets of 250 mg each. The tablets should not be crushed or chewed, and should be swallowed whole. It is being repackaged by RemedyRepack Inc. and should be stored at 20-25°C (88-77°F); excursions permitted o 15-30°C (59-86°F) [See USP]. The direction for usage can be found in the package insert. Keep this and all medication out of the reach of children. Lot number and expiration date information is provided.*
FDA Label Image

Chemical Structure (Divalproex 01)

Chemical Structure (Divalproex 01)
FDA Label Image

Figure 1 (Divalproex 02)

Figure 1 (Divalproex 02)
The text seems to be a table or graph showing percentages and acronyms for studies. It is not possible to generate a useful description without more context.*
FDA Label Image

Figure 2 (Divalproex 03)

Figure 2 (Divalproex 03)
The text represents a chart or table comparing the reduction in CPS Rate for Divalproex sodium and Placebo. The chart shows percentages for improvement, no change, and worsening for both treatments. The percentages range from -50% to 100%.*
FDA Label Image

Figure 3 (Divalproex 04)

Figure 3 (Divalproex 04)
This document appears to be a graph showing the percentage reduction in CPS (Central Pain Syndrome) rate with high and low doses of treatment. There is also a visual representation of the percentage of patients experiencing improvement or worsening in their condition, as well as those experiencing no change.*
FDA Label Image

Figure 4 (Divalproex 05)

Figure 4 (Divalproex 05)
The text is not useful as it consists of only a few drug names and study references. It does not contain any contextual information or complete sentences to provide a description.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.